Analyst Insight Alerts: Angie’s List, Arena Pharma, SM Energy, NuVasive, Analog Devices

Angie’s List Inc (NASDAQ:ANGI): After Angie’s List reported higher than expected Q4 revenue but lower than expected EPS, ThinkEquity believes that the company’s recurring revenue base is large enough to begin to offset its high marketing costs. The firm maintains a $22 target and Buy rating.

Arena Pharmaceuticals, Inc.(NASDAQ:ARNA): Piper Jaffray views the FDA panel vote in favor of QNEXA approval as positive for Arena Pharmaceuticals (NASDAQ:ARNA). Piper thinks an FDA panel vote could be set for Arena’s weight loss drug lorcaserin on May 10 and views the risk/reward on shares as favorable.

SM Energy Company(NYSE:SM): After SM reported higher than expected Q4 EPS, BMO Capital raised its estimate of the company’s valuation by about 10%. The firm believes that the company can beat its 2012 guidance, and it continues to identify the stock as a top pick.

NuVasive, Inc.(NASDAQ:NUVA): Piper Jaffray believes shares of NuVasive are positioned to move higher with the company’s Q4 results and 2012 guidance out of the way. The firm lowered its price target for the name to $33 from $35 but finds shares as attractive at current levels.

Analog Devices Inc.(NYSE:ADI): Baird raised its price target on Analog Devices following Q1 results. The firm cited improved fundamentals, strong positioning, and strong product portfolio. Shares are Outperform rated.

Want news like this in real-time so you can get an edge? Click here for Wall St. Cheat Sheet Pro.

To contact the reporter on this story: Derek Hoffman at staff.writers@wallstcheatsheet.com

To contact the editor responsible for this story: Damien Hoffman at editors@wallstcheatsheet.com